Cutia Therapeutics
科笛集团
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2487)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 5 JUNE 2025

At the annual general meeting (the "**AGM**") of Cutia Therapeutics (the "**Company**") held on 5 June 2025, all the proposed resolutions as set out in the notice of the AGM dated 22 April 2025 were taken by poll. The poll results are as follows:

Ordinary Resolutions		Number of Votes (%)(Note (a))	
		For	**Against**
1.	To receive the audited consolidated financial statements of the Company and the reports of the directors (the "**Director(s)**") and auditors of the Company for the year ended 31 December 2024.	241,204,575 (100.00%)	0 (0.00%)
2(a).	To re-elect Ms. Zhang Lele as an executive Director of the Company.	241,204,575 (100.00%)	0 (0.00%)
2(b).	To re-elect Mr. Huang Yuqing as an executive Director of the Company.	241,204,575 (100.00%)	0 (0.00%)
2(c).	To re-elect Dr. Xie Qin as a non-executive Director of the Company.	226,003,180 (93.70%)	15,201,395 (6.30%)
2(d).	To authorise the board of Directors of the Company to fix the respective Directors' remuneration.	241,204,575 (100.00%)	0 (0.00%)
3.	To re-appoint Ernst & Young as auditor of the Company and to authorise the board of Directors to fix their remuneration.	241,204,575 (100.00%)	0 (0.00%)
4.	To give a general mandate to the Directors to repurchase shares of the Company not exceeding 10% of the total number of issued shares of the Company (excluding any treasury shares) as at the date of passing of this resolution.	241,204,575 (100.00%)	0 (0.00%)

Ordinary Resolutions		Number of Votes (%)[Note (a)]	
		For	Against
5.	To give a general mandate to the Directors to issue, allot and deal with additional shares of the Company not exceeding 20% of the total number of issued shares of the Company (excluding any treasury shares) as at the date of passing of this resolution.	237,770,775 (98.58%)	3,433,800 (1.42%)
6.	To extend, conditional upon the passing of resolutions no. 4 and 5, the general mandate granted to the Directors to issue, allot and deal with additional shares in the capital of the Company by the aggregate number of the shares repurchased by the Company.	222,576,380 (92.28%)	18,628,195 (7.72%)

Notes:

(a) The number and percentage of votes are based on the total number of shares of the Company voted by the shareholders of the Company at the AGM in person or by proxy.

(b) As a majority of the votes were cast in favour of each of the ordinary resolutions nos. 1 to 6, all the ordinary resolutions at the AGM were duly passed.

(c) As at the date of AGM, a total of 320,359,111 shares of the Company were in issue, which included 1,362,600 treasury shares (including any treasury shares held or deposited in the Central Clearing and Settlement System) and no shares that the Company had repurchased but not yet cancelled. The aforementioned treasury shares were excluded from the total number of issued shares entitled to attend the AGM and vote on the resolutions presented at the meeting, and the Company did not exercise voting rights for such shares at the AGM. As a result, the total number of shares entitling the holder to attend the AGM and vote for or against the proposed resolutions at the meeting was 318,996,511 shares.

(d) There were no shares entitling the holder to attend and abstain from voting in favour of the resolutions at the AGM as set out in rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**").

(e) No shareholder of the Company was required under the Listing Rules to abstain from voting in respect of any of the proposed resolutions at the AGM.

(f) None of the shareholders of the Company have stated their intention in the Company's circular dated 22 April 2025 to vote against or to abstain from voting on any of the resolutions at the AGM.

(g) The Company's branch share registrar in Hong Kong, Tricor Investor Services Limited, acted as the scrutineer for the vote-taking at the AGM.

(h) All Directors attended the AGM in person or by electronics means.

By order of the Board
Cutia Therapeutics
Zhang Lele
Chief Executive Officer and Executive Director

Hong Kong, 5 June 2025

As at the date of this announcement, the board of Directors comprises (i) Ms. Zhang Lele and Mr. Huang Yuqing as executive directors; (ii) Dr. Chen Lian Yong, Dr. Xie Qin, Dr. Huang Xiao and Ms. Yang Yunxia as non-executive directors; and (iii) Mr. Chung Ming Kit, Mr. Tao Tak Yan Dennis and Mr. Ye Xiaoxiang as independent non-executive directors.